New 'Four-in-One' antibody takes on Hard-to-Treat lymphoma

NCT ID NCT05623982

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called GNC-038, a tetra-specific antibody designed to target cancer cells in people with Non-Hodgkin's lymphoma that has come back or not responded to treatment. About 40 adults will receive the drug by IV to see if it is safe and can shrink tumors. The goal is to find the best dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNC-038 (a tetra-specific antibody given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for people with Non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Harbin First Hospital
RECRUITING

Haerbin, Heilongjing, China
Qingdao Central Hospital
RECRUITING

Qingdao, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.